Selecta/JDRF Collaboration Seeks Vaccine To Prevent Or Treat Type 1 Diabetes
This article was originally published in The Pink Sheet Daily
JDRF will provide milestone-based financial support toward preclinical proof of concept for a tolerogenic vaccine candidate.
You may also be interested in...
European economists meeting in London discuss drug innovation’s costs to the larger health system, research funding sources, and “sin taxes.”
Vaccine and immunotherapy-focused Selecta, up to now focused on grants for funding, signs its first big pharma partner around targeted, antigen-specific programs for undisclosed allergies.
With BIO 2012 taking place June 17-21, the entire health care world awaits the Supreme Court’s ruling on health care reform. In the pharma world, companies are strategizing against all the possible outcomes.